SEC-sourced researchBeta
ZNTL
Zentalis Pharmaceuticals, Inc.
Company comparison ↗
Data passport
- CIK
- 0001725160
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Oct 1, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 0.0000 | Mar 26, 2026 |
| December 2024 | 67,425,000.0000 | Mar 26, 2026 |
| December 2025 | 0.0000 | Mar 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 0.0000 | -137,060,000.0000 | -125,247,000.0000 | 288,967,000.0000 | 72,763,000.0000 | Mar 26, 2026 |
| December 2024 | 67,425,000.0000 | -165,839,000.0000 | -170,860,000.0000 | 430,337,000.0000 | 93,151,000.0000 | Mar 26, 2026 |
| December 2023 | 0.0000 | -292,191,000.0000 | -207,822,000.0000 | — | — | Mar 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $0 | December 2025 | Mar 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $67.43M | December 2024 | Mar 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$137.06M | December 2025 | Mar 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$125.25M | December 2025 | Mar 26, 2026 | 10-K |
| Total assetsAssets | $288.97M | December 2025 | Mar 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $72.76M | December 2025 | Mar 26, 2026 | 10-K |